Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

By D. Loblaw, Katherine S. Virgo, R. Nam, M. Somerfield, E. Ben-Josef, D. Mendelson, R. Middleton, S. Sharp, Thomas J. Smith, J. Talcott and 5 more. Journal of Clinical Oncology, 2007

600 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2f518b8928cc5a30bab60ebe09dd86922f73027c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Harris
2. E. Mostaghel
3. P. Nelson
4. B. Montgomery

Citations in the corpus

• Prostate Cancer (2018, unknown): “It is applied as first-line therapy in patients with metastatic disease, and increasingly in the adjuvant situation subsequent to radiotherapy in curative intent [14] .”
• Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion (2009, background): “This target is defined on the basis of the level of suppression achieved with surgical castration, and remains the benchmark for evaluating the efficacy of agents such as GnRH agonists”